- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03509441
Early MRI Detection of Myocardial Deterioration as a Preventive, Disease Staging, and Prognostic Biomarker in Insulin Resistance
Study Overview
Status
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Esha Roy, BS
- Phone Number: 408-313-7538
- Email: esharoy@stanford.edu
Study Contact Backup
- Name: Rajesh Dash, MD, PhD
- Phone Number: 650-723-8138
- Email: rhombus@stanford.edu
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- South Asian
Exclusion Criteria:
- Pregnant women
- Patients with prior diagnoses of diabetes
- Patients on insulin therapy
- Patients with known coronary heart disease or other non-ischemic cardiomyopathies
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
---|
South Asians with Insulin Resistance
125 patients (anticipated)
|
South Asians without Insulin Resistance
125 patients (anticipated)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identifying patients with high fibrosis levels using peripheral blood samples
Time Frame: Blood samples drawn once at baseline visit
|
The investigators will collect and store peripheral blood samples from every patient, identify those with high and low fibrosis levels using our described protocol, and then select patients with disproportionately high fibrosis levels given their disease burden. The investigators can test for the level of fibrosis by generating induced pluripotent stem cell-derived cardiomyocytes (iPSC- CMs) from these collected blood samples. These iPSC-CMs will be tested, in vitro, for drug sensitivity, susceptibility to apoptotic stimuli, and the propensity to produce pro-fibrotic cytokine activation- all factors which will help the investigators determine fibrosis levels. |
Blood samples drawn once at baseline visit
|
Insulin Sensitivity measured by OGTT
Time Frame: OGTT done at baseline/ first visit
|
An oral glucose tolerance test with insulin measurement (OGTT) will be performed for all the patients.
The investigators will draw blood to determine a fasting glucose measurement, and then the patients will be given a 75 g glucose solution to drink.
Blood samples will be collected at serial time points (30 minutes, 60 minutes, 120 minutes) after ingestion of this liquid to determine blood glucose and insulin levels.
The OGTT will help investigators determine the patient's degree of insulin sensitivity.
|
OGTT done at baseline/ first visit
|
Insulin Sensitivity measured by Fasting Lipid Panel
Time Frame: Lipid Panel done at baseline/ first visit
|
Baseline fasting lipids will be assessed to calculate a TG/HDL-C ratio, which also correlates with the degree of insulin sensitivity or lack thereof.
These results will be correlated to the insulin sensitivity assessment performed by the OGTT.
|
Lipid Panel done at baseline/ first visit
|
Left ventricular volume
Time Frame: CMR done at baseline visit
|
Cardiac MRI/ CMR done to noninvasively image heart and determine volume of left ventricle
|
CMR done at baseline visit
|
Left ventricular mass
Time Frame: CMR done at baseline visit
|
Cardiac MRI/ CMR done to noninvasively image heart and determine mass of left ventricle
|
CMR done at baseline visit
|
Ejection fraction %
Time Frame: CMR done at baseline visit
|
Cardiac MRI/ CMR done to noninvasively image heart and determine ejection fraction
|
CMR done at baseline visit
|
Myocardial tagging for strain analysis
Time Frame: CMR done at baseline visit
|
Cardiac MRI/ CMR done to noninvasively image heart and assess ventricular function through myocardial tagging.
By modulating the magnetization gradient of the MRI prior to acquiring images, any parts of the heart which are not contracting can be identified.
These images will be analyzed via strain analysis for such abnormalities in function
|
CMR done at baseline visit
|
Assessing diffuse fibrosis via T1 mapping
Time Frame: CMR done at baseline visit
|
A CMR technique called T1 mapping will be performed to calculate level of extracellular volume (ECV), which helps with the quantification of diffuse fibrosis
|
CMR done at baseline visit
|
Assessing level of edema via T2 mapping
Time Frame: CMR done at baseline visit
|
A CMR technique called T1 mapping will be performed assess amount of edema in the heart
|
CMR done at baseline visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Collagen turnover assessment
Time Frame: Blood drawn at baseline visit
|
Patients will have blood drawn for serum measurement of propeptides of several procollagens to determine the level of collagen turnover
|
Blood drawn at baseline visit
|
Endothelial Function
Time Frame: 15 minute procedure done at baseline visit
|
The investigators will also measure endothelial function using the endoPAT device, which employs noninvasive measurement of finger arterial pulsatile volume changes as a measure of endothelial function.
This test takes approximately 15 minutes and is noninvasive.
|
15 minute procedure done at baseline visit
|
Urine test for albumin levels
Time Frame: One urine test done at baseline visit
|
24 Hour urine test for assessment of albumin levels
|
One urine test done at baseline visit
|
Urine test for creatinine levels
Time Frame: One urine test done at baseline visit
|
24 Hour urine test for assessment of creatinine levels
|
One urine test done at baseline visit
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Abha Khandelwal, MD, Stanford University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 31279
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom